{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:52:19Z","timestamp":1648734739469},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T00:00:00Z","timestamp":1178582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This report regards the case of a 43 year-old HIV-positive woman who developed an episode of serious transaminase elevation during stavudine-including antiretroviral therapy. Diagnostic assessment ruled out hepatitis virus co-infection, alcohol abuse besides other possible causes of liver damage. No signs of lactic acidosis were present. Liver biopsy showed portal inflammatory infiltrate, spotty necrosis, vacuoles of macro- and micro-vesicular steatosis, acidophil and foamy hepatocytes degeneration with organelles clumping, poorly formed Mallory bodies and neutrophil granulocytes attraction (satellitosis). A dramatic improvement in liver function tests occurred when stavudine was discontinued and a new antiretroviral regimen with different nucleoside reverse transcriptase inhibitors was used. The importance of considering hepatotoxicity as an adverse event of HAART including stavudine, even in absence of other signs of mitochondrial toxicity should therefore be underlined. Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage.<\/jats:p>","DOI":"10.1186\/1752-1947-1-19","type":"journal-article","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T18:13:58Z","timestamp":1178648038000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report"],"prefix":"10.1186","volume":"1","author":[{"given":"Giuseppe","family":"Lapadula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Costarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Cologni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Bercich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Casari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gambarotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,8]]},"reference":[{"key":"19_CR1","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","volume":"44","author":"M Nunez","year":"2006","unstructured":"Nunez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006, 44: S132-S139. 10.1016\/j.jhep.2005.11.027.","journal-title":"J Hepatol"},{"key":"19_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.taap.2004.03.005","volume":"199","author":"LW Velsor","year":"2004","unstructured":"Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ: Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol. 2004, 199: 10-19. 10.1016\/j.taap.2004.03.005.","journal-title":"Toxicol Appl Pharmacol"},{"key":"19_CR3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","volume":"46","author":"G Birkus","year":"2002","unstructured":"Birkus G, Hitchcock MJ, Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002, 46: 716-723. 10.1128\/AAC.46.3.716-723.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"19_CR4","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1097\/00002030-200012220-00011","volume":"14","author":"BM den","year":"2000","unstructured":"den BM, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van LR, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000, 14: 2895-2902. 10.1097\/00002030-200012220-00011.","journal-title":"AIDS"},{"key":"19_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2334-5-58","volume":"5","author":"C Torti","year":"2005","unstructured":"Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo CS, Di PG, Filice G, Tinelli C, Carosi G: Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis. 2005, 5: 58-10.1186\/1471-2334-5-58.","journal-title":"BMC Infect Dis"},{"key":"19_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1310\/2L6M-EE7G-5PGN-FJYP","volume":"4","author":"C Livry","year":"2003","unstructured":"Livry C, Binquet C, Sgro C, Froidure M, Duong M, Buisson M, Grappin M, Quantin C, Portier H, Chavanet P, Piroth L: Acute liver enzyme elevations in HIV-1-infected patients. HIV Clin Trials. 2003, 4: 400-410. 10.1310\/2L6M-EE7G-5PGN-FJYP.","journal-title":"HIV Clin Trials"},{"key":"19_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000, 283: 74-80. 10.1001\/jama.283.1.74.","journal-title":"JAMA"},{"key":"19_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00126334-200303010-00004","volume":"32","author":"M Puoti","year":"2003","unstructured":"Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F, Carosi G: Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003, 32: 259-267. 10.1097\/00126334-200303010-00004.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"19_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00001432-200002000-00002","volume":"13","author":"K Brinkman","year":"2000","unstructured":"Brinkman K, Kakuda TN: Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?. Curr Opin Infect Dis. 2000, 13: 5-11.","journal-title":"Curr Opin Infect Dis"},{"key":"19_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0188-4409(02)00454-X","volume":"34","author":"P Cornejo-Juarez","year":"2003","unstructured":"Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P: Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res. 2003, 34: 64-69. 10.1016\/S0188-4409(02)00454-X.","journal-title":"Arch Med Res"},{"key":"19_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1086\/505495","volume":"43","author":"BH McGovern","year":"2006","unstructured":"McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT, Sax PE, Graeme-Cook F, Hibberd PL: Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006, 43: 365-372. 10.1086\/505495.","journal-title":"Clin Infect Dis"},{"key":"19_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/01.aids.0000163935.99401.25","volume":"19","author":"MS Sulkowski","year":"2005","unstructured":"Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005, 19: 585-592.","journal-title":"AIDS"},{"key":"19_CR13","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","volume":"20","author":"GJ Moyle","year":"2006","unstructured":"Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006, 20: 2043-2050. 10.1097\/01.aids.0000247574.33998.03.","journal-title":"AIDS"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-1-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-1-19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-1-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-1-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T08:17:06Z","timestamp":1630484226000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-1-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-1-19","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,8]]},"assertion":[{"value":"15 January 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}